Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports

Journal of Medical Case Reports

Walter E Haefeli²  Matthias Gorenflo¹  Jürgen Burhenne²  Yeliz Enderle²  Julia Winter¹  Alexandra Carls² 

[1] Department of Pediatric Cardiology and Congenital Heart Diseases, University of Heidelberg, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany;Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

关键词: Sublingual;    Sildenafil;    Pulmonary hypertension;    Plasma concentration;    Enteral;   

Others  :  817702
DOI  :  10.1186/1752-1947-8-171

 received in 2013-12-11, accepted in 2014-03-17,  发布年份 2014

【 摘 要 】

Introduction

Pulmonary hypertension is a progressive disease of diverse origin with devastating consequences in adults as well as in children. The phosphodiesterase 5 inhibitor sildenafil successfully lowers pulmonary vascular resistance. However, because of its poor enteral absorption, resulting in ineffective plasma concentrations, responses in infants and children are often erratic.

Case presentations

We report the cases of two Caucasian boys, one born at term (case 1) and one aged 2.5 years (case 2), who had structural cardiac and pulmonary defects accompanied by symptomatic pulmonary hypertension. They received sildenafil enterally and sublingually and also intravenously in one of them. Plasma samples were taken at various time points to determine the plasma concentrations of sildenafil and its partially active metabolite. Sildenafil and N-desmethyl sildenafil were quantified using a validated liquid chromatography/mass spectrometry method. Oxygen partial pressure was determined from routine arterial blood gas samples.

Conclusion

In agreement with previous observations in adults, we found that sublingual sildenafil was more extensively absorbed in our two pediatric patients. After sublingual administration, sildenafil plasma concentrations increased by 314% to 361% compared to enteral dosing. Concurrently, the metabolic ratio increased, suggesting not only that the overall absorption was enhanced but also that first-pass metabolism was partially bypassed. In case 2, the free fraction of sildenafil was 0.9%, which is considerably less than in adults (4%), suggesting that, in case 2, higher plasma concentration would have been needed to achieve effects similar to those in adults. Sublingual sildenafil appears to be a promising alternative route of administration in children with poor enteral absorption.

【 授权许可】

   
2014 Carls et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Wardle AJ, Tulloh RM: Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Arch Dis Child Educ Pract Ed 2013, 98:141-147.
• [2]Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002, 53(Suppl 1):5S-12S.
• [3]Ahsman MJ, Witjes BC, Wildschut ED, Sluiter I, Vulto AG, Tibboel D, Mathot RA: Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed 2010, 95:F109-F114.
• [4]Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN: Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. J Am Coll Cardiol 2010, 55:1456-1462.
• [5]Lammers AE, Haworth SG, Pierce CM: Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. Cardiol Young 2006, 16:84-86.
• [6]Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL: Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 2011, 37:502-509.
• [7]Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM: Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011, 4:198-206.
• [8]Nahata MC, Morosco RS, Brady MT: Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm 2006, 63:254-257.
• [9]Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL: A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012, 125:324-334.
• [10]US Food and Drug Administration: FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension. Silver Spring, MD: FDA; 2012. Available at http://www.fda.gov/drugs/drugsafety/ucm317123.htm webcite (accessed 25 March 2014)
• [11]Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B, Feinstein J, Fineman J, Raj U, Humpl T, Pediatric Pulmonary Hypertension Network (PPHNet): Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013, 187:572-575.
• [12]De Siati M, Saugo M, Franzolin N: The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction. Arch Ital Urol Androl 2003, 75:18-20.
• [13]Freitas AF Jr, Bacal F, Oliveira JL Jr, Santos RHB, Moreira LFP, Silva CR, Mangini S, Carneiro RMD, Fiorelli AI, Bocchi EA: [Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure] [in English Portuguese and Spanish]. Arq Bras Cardiol 2009, 92:116-126.
• [14]Zayed R, Kamel AO, Shukr M, El-Shamy A: An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. Acta Pharm 2012, 62:411-432.
• [15]Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000, 50:99-107.
• [16]Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 2002, 53(Suppl 1):21S-30S.
• [17]de Wildt SN: Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011, 7:935-948.
• [18]Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM: Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 2007, 82:265-274.
• [19]Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001, 51:239-248.
• [20]Karatza AA, Bush A, Magee AG: Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005, 100:267-273.